Skip navigation

Innovative Models to Advance Medical Science and Interact Compliantly with Key Thought Leaders

April 19-20, 2016
  • Philadelphia, PA

CBI’s Engaging in Scientific Communication with NPs and PAs conference offers attendees the opportunity to benchmark with peers on strategies for optimizing interactions with non-physician healthcare providers. The role of NPs and PAs has continued to evolve and due to their prescribing power, pharmaceutical companies have begun to take a greater interest in these HCPs. A variety of topics will be covered ranging from the extension of the Sunshine Act to tactics for effectively engaging and compliantly collaborating with non-physician prescribers.

Elite Speaking Faculty Includes:

Thomas Prevoznik
Unit Chief of Liaison,
Office of
Diversion Control
Drug Enforcement Administration

Kathleen Chavanu,
Senior Director,
Medical Communications,
Medical Affairs
Takeda Pharmaceuticals

Cindy Cooke, DNP,
FNP-C, FAANP
President
American Association
of Nurse Practitioners

Jeffrey A. Katz,
PA-C, DFAAPA
President, Chair of
the Board of Directors
American Academy of
Physician Assistants

Ruth Haile-Meskale,
Pharm.D., MBA
Medical Science Liaison
ZS Pharma, Inc.

Amy Kemner,
Senior Director, US Health Outcomes Strategy,
Group Head, Customer Engagement and Insights
GlaxoSmithKline

Paul Rowe, M.D.
Vice President,
Global Medical Affairs Head, Respiratory
Sanofi-Genzyme

Shawna Blasing
Regional Associate Director, Medical Affairs
Takeda Pharmaceuticals USA

Collaborate with Peers and Industry Leaders on the Most Effective Strategies for Interacting with NPs and PAs:

  • Understand NPs and PAs influence over patient care and treatment plans
  • Anticipate the effects of pending legislation extending the Sunshine Act to NPs and PAs
  • Evaluate strategies for effectively targeting and approaching non-physician stakeholders
  • Identify the impact of non-physician practitioners’ ability to prescribe controlled substances
  • Leverage conversations with NPs and PAs to focus on disease state, patient outcomes, treatment plans, side effect management and drug administration

Previous Attendee Acclaim:

I now have an improved understanding of the roles and responsibilities of NPs and PAs as healthcare providers.

Manager, Merck & Co.

The Program definitely added to my knowledge base.

Product Manager, Ther-RX

Very interesting info for targeting and the importance of targeting to NPs and PAs.

Specialist, Franklin Group

Very interesting having pharma companies and their customers (NPs/PAs) together was very helpful.

Specialist, AstraZeneca

The legal sampling info was relevant and useful to me in understanding the state of policies.

Director of Sample Management, Abbott

I learned as much by networking as I did from the presentations.

Director of Medical Information, Astellas

April 19-20, 2016 Wyndham Historic District Philadelphia, PA